Day: February 25, 2021

Worldwide Ocaliva®net sales of $83.3 million and $312.7 million for the fourth quarter and full year 2020, representing 18% and 25% growth over the prior yearIntercept provides initial 2021 Worldwide Ocaliva Net Sales Guidance of $325 million to $355 million and Non-GAAP Adjusted Operating Expense Guidance of $380 to $410 millionFDA interactions remain ongoing regarding newly identified safety signal (NISS) for liver disorder in a subset of PBC patients with cirrhosis; Update to Ocaliva label expected  Anticipated readout of REVERSE Phase 3 study in compensated cirrhosis due to NASH by end of 2021        Conference call scheduled for 8:30 a.m. ET todayNEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...

Fourth Quarter HighlightsPer Class B share(3): $0.84 adjusted basic earnings up 25.4%; $0.81 basic earnings up 37.3%; currency translation neutralSales increased 5.7% on 2.5% organic growth, 0.4% positive currency translation, and 2.8% acquisition growthOperating income improved 22.7%, with a 15.8% operating margin(1)up 220 bpsAnnual dividend increase of 16.7% effective March 17, 20212020 HighlightsPer Class B share(3): a record $3.08 adjusted basic earnings, up 10.4%; $2.96 basic earnings up 10.4%; currency translation positive $0.01Sales decreased 1.5% due to 3.9% organic decline, partially offset by acquisition-growth of 2.1% and 0.3% positive currency translationOperating income(1)increased 4.6%, with a 15.7% operating margin(1)up 90 bpsConsolidated leverage ratio improved to 1.24 for 2020TORONTO, Feb. 25, 2021 (GLOBE NEWSWIRE) —...

BOSTON and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following virtual investor conferences:Cowen 41st Annual Healthcare Conference on March 4, 2021, at 10:30 AM ET as part of a panel discussion focused on disorders of the central nervous systemBarclays 2021 Global Healthcare Conference on March 11, 2021, at 8:35 AM ETOppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 8:00 AM ETLive webcasts of the Barclays and Oppenheimer presentations will be available under “News & Events” in the Investors & Media section of the company’s website at www.orchard-tx.com. Webcast replays will be archived on the Orchard website following these presentations.About OrchardOrchard...

DAYTONA BEACH, Fla., Feb. 25, 2021 (GLOBE NEWSWIRE) — Brown & Brown, Inc. (NYSE: BRO) launches Bridge Specialty Group to encompass its broad portfolio of wholesale brands.“Bridge Specialty Group provides us with a platform to present a unified view to our retail partners across our more than 25 wholesale brands and 45 locations throughout the U.S. and London,” said Stephen M. Boyd, President of Bridge Specialty Group. “At Bridge Specialty Group, we will look to leverage our placement of over $3 billion in premium volume across more than 180 excess and surplus lines carrier partners to continuously introduce solutions that meet the evolving needs of our agency partners,” stated Boyd. “Bridge Specialty Group provides us the ability to bring together the collective market breadth and talents of our nearly 1,500 insurance professionals,...

EDINBURG, Va., Feb. 25, 2021 (GLOBE NEWSWIRE) — Shenandoah Telecommunications Company (“Shentel”) (Nasdaq: SHEN) announced fourth quarter and full year 2020 financial and operating results.2020 Highlights  Record Broadband data net additions of approximately 18,800 with Glo Fiber and Beam contributing approximately 4,000 and 100, respectivelyAdded approximately 27,000 Glo Fiber homes passed and eight new franchise agreements expanding franchise passings to over 116,000Launched Beam fixed wireless broadband service in the fourth quarter 2020 to approximately 9,400 homes passed in four counties in Virginia“2020 was a very successful and pivotal year for our Company, as we built momentum executing our Broadband strategy. Our incumbent cable business had a record year of data net additions, driven by our upgraded DOCSIS 3.1 cable network,...

TORONTO, Feb. 25, 2021 (GLOBE NEWSWIRE) — STORAGEVAULT CANADA INC. (“StorageVault” or the “Corporation”) (SVI-TSX-V) today reported the Corporation’s full year 2020 audited results. Iqbal Khan, Chief Financial Officer, commented:“StorageVault continues to show the resiliency of our business and the strength of our amazing team across the country delivering solid growth in fiscal 2020. These results were achieved in spite of the pandemic where for a portion of the year we experienced lower rental activity and paused rent increases and all fees. Our focus continues to be on growing free cash flow through integrating, improving and innovating operations and completing accretive acquisitions. We significantly beat our acquisition target with $232.7 million in acquisitions. We exceeded expectations by finishing Q42020 with same store...

The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that will be given to Phase 1 participants to evaluate the safety and tolerability of a booster vaccineDiscussions with regulatory authorities are ongoing regarding an additional registration-enabling study using an mRNA vaccine with a variant sequence; this would provide a flexible solution for rapidly adapting the vaccine for use against the B.1.351 lineage or other new strains that may emerge as possible immune escape virus variants Based on in-vitro studies conducted to date and observations from real world evidence, the Companies have not observed changes to neutralizing antibody levels that would predict a significant reduction in protection provided by two doses of BNT162b2New York and Mainz, Germany,...

Die Verabreichung einer dritten Dosis des Pfizer-BioNTech COVID-19-Impfstoffs BNT162b2 wird als Teil der Phase-1/2/3-Studie untersucht; die Teilnehmer der Phase-1-Studie erhalten eine 30µg-Dosis BNT162b2 zur Beurteilung der Sicherheit und Wirksamkeit als AuffrischungsimpfungLaufender Austausch mit Zulassungsbehörden über eine zusätzliche zulassungsrelevante Studie zum Einsatz eines mRNA-Impfstoffs mit einer variablen Sequenz; dies würde eine flexible Lösung für die schnelle Anpassung des Impfstoffs im Einsatz gegen die B.1.351-Linie oder andere neue Stämme darstellen, die als mögliche Immun-Escape-Virusvarianten auftreten könnten Die Unternehmen haben bisher in den durchgeführten in-vitro-Studien und anhand von Daten aus der praktischen Anwendung keine Veränderungen der neutralisierenden Antikörperlevel beobachten können, die auf eine...